Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1661216

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to Parkinson UK's UK Parkinson's Audit, published in 2022, what assessment he has made of the implications for his policies of that report's findings on the proportion of patients who received their medication on time; and if he will make a statement.
tabling member constituency	North Tyneside
tabling member printed	Mary Glindon
uin	199962
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>Within secondary care, hospital providers are responsible for ensuring that patients within hospital settings, including those with Parkinson’s disease, receive the appropriate medication on time.</p><p>NHS England has published a RightCare toolkit which aims to address challenges in providing services for those with progressive neurological conditions, including Parkinson’s disease. The toolkit provides advice on medicine optimisation, highlighting the importance of timely administration of specific drugs, such as Levodopa, in acute and community health settings.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 199964 question first answered 16/10/2023 08:43:48 answering member 4423 label Biography information for Will Quince
tabling member	4126 label Biography information for Mary Glindon

1661218

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his Department's policies of Parkinson's UK's report entitled Every minute counts: Time critical Parkinson’s medication on time, every time, published in September 2023; and if he will make a statement.
tabling member constituency	North Tyneside
tabling member printed	Mary Glindon
uin	199964
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>Within secondary care, hospital providers are responsible for ensuring that patients within hospital settings, including those with Parkinson’s disease, receive the appropriate medication on time.</p><p>NHS England has published a RightCare toolkit which aims to address challenges in providing services for those with progressive neurological conditions, including Parkinson’s disease. The toolkit provides advice on medicine optimisation, highlighting the importance of timely administration of specific drugs, such as Levodopa, in acute and community health settings.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 199962 question first answered 16/10/2023 08:43:48 answering member 4423 label Biography information for Will Quince
tabling member	4126 label Biography information for Mary Glindon

1237065

registered interest
date	23/09/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when his Department last reviewed reimbursement prices for pharmaceutical companies licensed to supply entacapone only products.
tabling member constituency	North Tyneside
tabling member printed	Mary Glindon
uin	94417
answer	answer is ministerial correction date of answer 22/10/2020 answer text <p>Reimbursement prices paid to community pharmacies for dispensed medicines are reviewed on a monthly basis. For example, the reimbursement price for entacapone was recently reviewed for October. Due to fluctuations in selling prices, there is also a mechanism which allows for reimbursement prices to be reviewed in month. These reimbursement prices are referred to as concessionary prices. Entacapone 200 milligram tablets were granted a concessionary price in August.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 22/10/2020 14:40:46 answering member 4380 label Biography information for Jo Churchill previous answer version 50380 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
tabling member	4126 label Biography information for Mary Glindon

1237066

registered interest
date	23/09/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if they will make an assessment of the potential merits for supply stabilisation of recategorising entacapone only products to category C in the NHS drugs tariff; and if he will make a statement.
tabling member constituency	North Tyneside
tabling member printed	Mary Glindon
uin	94418
answer	answer is ministerial correction date of answer 22/10/2020 answer text <p>Entacapone 200 milligram (mg) tablets are currently listed in Category M of Part VIII of the Drug Tariff. Reimbursement prices of generic medicines in Category M are calculated on the basis of sales and volume data provided from manufacturers and they also include an element of medicine margin. For a product to be considered for addition to a category or to move from one category to another – the guideline criteria relevant to the category in which the product may be placed needs to be met. This is constantly kept under review for all products listed in the Drug Tariff including entacapone 200mg tablets.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 22/10/2020 15:12:41 answering member 4380 label Biography information for Jo Churchill previous answer version 50381 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
tabling member	4126 label Biography information for Mary Glindon

1203900

registered interest
date	15/06/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that medications for Parkinson's disease are (a) available during the covid-19 outbreak and (b) at the end of the transition period.
tabling member constituency	North Tyneside
tabling member printed	Mary Glindon
uin	59457
answer	answer is ministerial correction date of answer 09/07/2020 answer text <p>As part of our concerted national efforts in response to the COVID-19 pandemic, we will continue doing everything we can to ensure patients continue to have access to safe and effective medicines, including those used in the treatment of Parkinson’s disease.</p><p>The Department has well-established procedures to deal with medicine shortages and is working closely with industry, the National Health Service and others in the supply chain to reduce the likelihood of future shortages resulting from COVID-19 or any other cause.</p><p>The Government, pharmaceutical industry and NHS will always work closely together to help ensure patients have access to the medicines and treatments they need under all scenarios including those medicines used in the treatment of Parkinson’s disease.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/07/2020 10:01:29 answering member 4380 label Biography information for Jo Churchill
tabling member	4126 label Biography information for Mary Glindon

1143007

registered interest
date	02/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many Medicines Usage Reviews have been undertaken for people with Parkinson's in each year since their introduction.
tabling member constituency	North Tyneside
tabling member printed	Mary Glindon
uin	284564
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>Since 2014, community pharmacy contractors have been required to conduct 70% of the Medicines Use Reviews (MURs) that they undertake on the following target groups and data is collected accordingly:</p><p>- Patients taking high-risk medicines (Non-steroidal anti-inflammatory drugs, anticoagulants, antiplatelets and diuretics);</p><p>- Patients recently discharged from hospital;</p><p>- Patients prescribed a respiratory drug, as specified; and</p><p>- Patients regularly prescribed four or more medicines, at least one of which is for a risk of cardiovascular disease, as specified.</p><p>Specific data is not collected on the remaining 30% and so it is not possible to say how many people taking medicines for Parkinson’s disease have received an MUR.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/09/2019 15:14:49 answering member 4380 label Biography information for Jo Churchill
tabling member	4126 label Biography information for Mary Glindon